Shares of Hims & Hers Health Inc. (HIMS) have demonstrated strong performance in 2025, trading approximately 149% higher year-to-date. Despite a recent pullback to the low $50 range, the stock rebounded above $60 and remains over 100% above its 200-day simple moving average, with a relative strength index (RSI) of 72, indicating strong momentum. Market participants note the stock's robust user interface and direct-to-consumer model, particularly in the growing obesity segment. Investors view HIMS as a long-term hold, often in conjunction with other obesity-focused companies such as Viking Therapeutics Inc. (VKTX), Eli Lilly and Company (LLY), and smaller positions in Kezar Life Sciences (KZR), G Protein-Coupled Receptors (GPCR), and Terns Pharmaceuticals (TERN). Viking Therapeutics is expected to have a notable period ahead with a Phase 3 trial start for a subcutaneous obesity drug and a Phase 2 readout for an oral obesity drug anticipated this quarter, which could significantly influence its share price. Eli Lilly is highlighted as a major outperformer in the pharmaceutical sector, largely due to its obesity drug, contrasting with peers like Pfizer (PFE), Merck (MRK), Regeneron Pharmaceuticals (REGN), Bristol-Myers Squibb (BMY), and AstraZeneca (AZN), which are trading near multi-year lows. The strong performance and investor interest in obesity-related therapeutics underscore the sector's growing importance within the pharmaceutical industry.